| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 02/22/2005 | US6858225 A mixture of lipids containing a protonatable or deprotonatable lipid, such as polyoxyethylene glycol or polyamide oligomer modified lipid, or amino lipid is combined with a buffered aqueous solution of a charged drug |
| 02/22/2005 | US6858224 Prevention of particle aggregation of a lipid/nucleic acid complex; obtain lipid complex, insert non-cationic lipid into complex, monitor aggregation |
| 02/22/2005 | US6858222 Fabrication of drug loaded biodegradable polymer fibers |
| 02/22/2005 | US6858220 Implantable microfluidic delivery system using ultra-nanocrystalline diamond coating |
| 02/22/2005 | US6858219 Methods for sterilizing male mammals |
| 02/22/2005 | US6858206 Methods for treating diseases caused by deficiencies of recombinant alpha-L-iduronidase |
| 02/22/2005 | US6858203 Treating of hyperphosphatemia by ingesting a ion exchanging resin comprising an allyl addition polymer having an amine salt or quaternary amine functional group; side effect reduction |
| 02/22/2005 | US6858199 High efficient delivery of a large therapeutic mass aerosol |
| 02/22/2005 | US6858166 Enteric coatings for drugs; sustained rlease |
| 02/22/2005 | US6858018 Iontophoretic devices |
| 02/22/2005 | CA2438438A1 Controlled release granules comprising porous silica core |
| 02/22/2005 | CA2184581C Improved dnase liquid solutions |
| 02/22/2005 | CA2150251C Lyospheres comprising gonadotropin |
| 02/22/2005 | CA2106423C Stabilized pharmaceutical compositions containing derivatives of vitamins d2 and d3 |
| 02/17/2005 | WO2005015158A2 T1r hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds |
| 02/17/2005 | WO2005014814A2 5’-and 3’-capped aptamers and uses therefor |
| 02/17/2005 | WO2005014698A1 Methods for the preparation of cross-linked polymer networks using coacervation and in situ cross-linking |
| 02/17/2005 | WO2005014697A1 Coated water-swellable material |
| 02/17/2005 | WO2005014110A1 Cpg-packaged liposomes |
| 02/17/2005 | WO2005014090A1 Methods of determining film thicknesses for an aerosol delivery article |
| 02/17/2005 | WO2005014071A1 Methods and devices for the treatment of intervertebral discs |
| 02/17/2005 | WO2005014048A1 Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids |
| 02/17/2005 | WO2005014047A1 Bioadhesive gel based on hydroxyethylcellulose |
| 02/17/2005 | WO2005014046A2 Compositions for delivery of therapeutics into the eyes and methods for making and using the same |
| 02/17/2005 | WO2005014044A1 Medicaments for inhalation comprising betamimetics and an anticholinergic |
| 02/17/2005 | WO2005014043A1 Chlorthalidone combinations |
| 02/17/2005 | WO2005014034A1 Stabilized formulation of parathyroid hormone |
| 02/17/2005 | WO2005014031A1 Use of calcitonin in osteoarthritis |
| 02/17/2005 | WO2005014013A1 Viscosity-stable bismuth-containing pharmaceutical compositions |
| 02/17/2005 | WO2005014010A1 Pharmaceutical composition comprising gemcitabine and cyclodextrines |
| 02/17/2005 | WO2005014005A1 Combination of an anticholinergic and a steroid and its use to treat respiratory disorders by inhalation |
| 02/17/2005 | WO2005013999A1 Medicaments for inhalation comprising steroids and a novel anticholinergic |
| 02/17/2005 | WO2005013992A1 Medicaments for inhalation comprising betamimetics and an anticholinergic agent |
| 02/17/2005 | WO2005013991A1 Dry syrup containing loratadine |
| 02/17/2005 | WO2005013987A1 Fexofenadine composition and process for preparing |
| 02/17/2005 | WO2005013971A1 Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences |
| 02/17/2005 | WO2005013968A1 Semi-solid formulations for the oral administration of taxoids |
| 02/17/2005 | WO2005013967A1 Medicaments comprising pde iv inhibitors and a novel anticholinergic and their use for treating respiratory disorders |
| 02/17/2005 | WO2005013964A1 Pharmaceutical preparation containing nateglinide |
| 02/17/2005 | WO2005013962A1 Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator |
| 02/17/2005 | WO2005013960A1 Preparing method for controlled released type tablet tamsulosin hcl and the tablet thereof |
| 02/17/2005 | WO2005013957A2 Solid dispersible and/or orodispersible non-filmy containing at least one type of active substance pharmaceutical composition and method for the preparation thereof |
| 02/17/2005 | WO2005013956A1 Novel composition comprising rosiglitazone and another antidiabetic agent |
| 02/17/2005 | WO2005013954A1 Modified release venlafaxine hydrochloride tablets |
| 02/17/2005 | WO2005013953A1 Extended release venlafaxine besylate tablets |
| 02/17/2005 | WO2005013948A2 Method of treating acute myocardial infarction |
| 02/17/2005 | WO2005013945A2 Medicaments for inhalation comprising steroids and a betamimetic |
| 02/17/2005 | WO2005013944A1 Flavored taste-masked pharmaceutical formulation made using a one-step coating process |
| 02/17/2005 | WO2005013943A1 Hydrophilic adhesive compositions for delivery of herbal medicines |
| 02/17/2005 | WO2005013942A1 Compositions comprising components coated with a liquid impermeable but gas permeable layer, use thereof for treating cutaneous and other exocrine gland diseases |
| 02/17/2005 | WO2005013941A1 Polysaccharide double-layer microcapsules as carriers for biologically active substance oral administration |
| 02/17/2005 | WO2005013940A1 Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin |
| 02/17/2005 | WO2005013939A1 Pharmaceutical composition containing water soluble drug |
| 02/17/2005 | WO2005013938A1 Process for producing drug ultramicroparticle and apparatus therefor |
| 02/17/2005 | WO2005013937A2 Novel compositions of sildenafil free base |
| 02/17/2005 | WO2005013936A2 Manufacture of long term drug delivery devices with polyurethane based polymers |
| 02/17/2005 | WO2005013935A2 Composition for releasing a weak base for an extended period of time |
| 02/17/2005 | WO2005013933A1 Mucoadhesive composition comprising polyacrylate and chemoattractant |
| 02/17/2005 | WO2005013919A2 Treatment using dantrolene |
| 02/17/2005 | WO2005013906A2 pH-RESPONSIVE FILM FOR INTRAVAGINAL DELIVERY OF A BENEFICIAL AGENT |
| 02/17/2005 | WO2005013896A2 Programmed immune responses using a vaccination node |
| 02/17/2005 | WO2005013891A2 Vaccines using pattern recognition receptor-ligand:lipid complexes |
| 02/17/2005 | WO2005013810A2 Biodegradable embolic agents |
| 02/17/2005 | WO2005013714A1 Palatable ductile chewable veterinary composition |
| 02/17/2005 | WO2005002540A3 Dry powder pharmaceutical suspension compositions of cefuroxime axetil |
| 02/17/2005 | WO2005000740A3 Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs |
| 02/17/2005 | WO2005000266A3 Liposomal formulations comprising a combination of two or more active agents |
| 02/17/2005 | WO2004110400A3 Implantable polymeric device for sustained release of nalmefene |
| 02/17/2005 | WO2004108884A3 Composite materials and particles |
| 02/17/2005 | WO2004103345A3 Particles which are stabilised in size by diacid copolymer |
| 02/17/2005 | WO2004100857A3 Highly plastic granules for making fast melting tablets |
| 02/17/2005 | WO2004095955A8 A flameless electronic atomizing cigarette |
| 02/17/2005 | WO2004091483A3 Once daily formulations of tetracyclines |
| 02/17/2005 | WO2004073645A3 Inhibition of olfatory neurosensory function of treat eating disorders and obesity |
| 02/17/2005 | WO2004072249A3 Polyvinylethers for delivery of polynucleotides to mammalian cells |
| 02/17/2005 | WO2004063705A3 Liquid-liquid interfacial nanoparticle assemblies |
| 02/17/2005 | WO2004056338A3 Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device |
| 02/17/2005 | WO2004052401A3 Compositions and methods of delivery of pharmacological agents |
| 02/17/2005 | WO2004002999A8 Modified 2' and 3' -nucleoside produgs for treating flaviridae infections |
| 02/17/2005 | US20050038505 Drug-delivery endovascular stent and method of forming the same |
| 02/17/2005 | US20050038492 Method for forming matrices of hardened material |
| 02/17/2005 | US20050038446 Thermal treatment to improve intraocular lens inserter lubricity |
| 02/17/2005 | US20050038415 Method and apparatus for the treatment of obesity |
| 02/17/2005 | US20050038378 Device and method for delivering or withdrawing a substance through the skin |
| 02/17/2005 | US20050038371 Controlled cerebrospinal infusion and shunt system |
| 02/17/2005 | US20050038239 Locked nucleic acid conjugate for use in treatment of cell proliferative disorders |
| 02/17/2005 | US20050038134 Crosslinked, water insoluble polymer; medical equipment, drug delivery, tissue engineering |
| 02/17/2005 | US20050038118 Treatment |
| 02/17/2005 | US20050038111 4'-cyano- alpha ', alpha ', alpha '-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m-toluidide; anti-oestrogen (eg, tamoxifen citrate) and/or an aromatase inhibitor (eg, anastrozole); preventing side effect; bioavailability; storage stability; prostate cancer |
| 02/17/2005 | US20050038108 4S, 5R, 6R)-5-Acetylamino-4-azido-6-[(S)-4-nitrophenoxycarbonyloxy)-(2-oxo-[1,3]dioxolan-4R-yl)methyl]- 5,6-dihydro-4H-pyran2-carboxylic acid methylester; modified at the carboxyl or hydroxyl or amino functions; orthomyxovirus and paramyxovirus infections; a long lung residency time and high potency |
| 02/17/2005 | US20050038103 improve visual acuity and visual field ; corneal dystrophy; cataracts; retinitis pigmentosa |
| 02/17/2005 | US20050038096 include a benzimidazole (mebendazole, fenbendazole, omeprazole), a polyol (polyethylene glycol), and a dipolar aprotic solvent (N,N-dimethylacetamide or dimethylsulfoxide); improved drug solubility, drug release from the formulation, and bioavailability |
| 02/17/2005 | US20050038077 use of pharmaceutically acceptable organic acids with a water solubility >1 g/250 mL at 20 degrees C., in solid oral formulations leads to a improved galenic form of ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate |
| 02/17/2005 | US20050038042 Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders |
| 02/17/2005 | US20050038039 Formulations |
| 02/17/2005 | US20050038022 Using a benzimidazole carbamate compound in lipid carrier; antitumor agents |
| 02/17/2005 | US20050038007 Adjust solubility; immediate release of HMG-COA reductase inhibitor and sustained release of cholesteryl ester transfer protein; anticholesterol agents |
| 02/17/2005 | US20050037994 Inclusion compounds of fumagillol derivative or its salt, and pharmaceutical compositions comprising the same |
| 02/17/2005 | US20050037506 Methods of determining film thicknesses for an aerosol delivery article |
| 02/17/2005 | US20050037374 uses nanoparticle-based assemblies, which comprise a nanoparticle, a surrogate marker and detectors; efficient and accurate means for diagnosing a condition, disease, or disorder and for focused treatment regimens; for identifying the presence of a target analyte/biomarker in a sample of bodily fluids |